Evidence map›Paper›PMID 36047714›Full record

ReviewEpigenetics2022

Aberrant regulation of CXCR4 in cancer via deviant microRNA-targeted interactions.

Alexei J Stuckel, Tripti Khare, Marc Bissonnette, Sharad Khare

Open access · greenAbstract readReview
In one paragraph

Review in Epigenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Alexei J StuckelDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri 65212, USA.
Tripti KhareDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri 65212, USA.
Marc BissonnetteSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, Chicago, Il 60637, USA.
Sharad KhareDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri 65212, USA.
University of Missouri · USUniversity of Chicago · US

Funding

CXCR4 as a target for colon cancer chemopreventionR01CA240710 · NCI · UNIVERSITY OF CHICAGO · PI BISSONNETTE, BRUCE MARC · 2019 to 2023
$1.8M
Deciphering the role of Sprouty2 in CRC progression, treatment and recurrenceR03CA249487 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI KHARE, SHARAD · 2020 to 2020
$146k
Colorectal Cancer: Characterization of a new Cre-LoxP ModelR03CA216160 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI KHARE, SHARAD · 2017 to 2018
$122k
BLRD VA I01 BX000824NCI NIH HHS R01 CA240710NCI NIH HHS R03 CA216160NCI NIH HHS R03 CA249487
6 · The paper itself

Abstract

CXCR4 is involved in many facets of cancer, including being a major player in establishing metastasis. This is in part due to the deregulation of CXCR4, which can be attributed to many genetic and epigenetic mechanisms, including aberrant microRNA-CXCR4 interaction. MicroRNAs (miRNAs) are a type of small non-coding RNA that primarily targets the 3' UTR of mRNA transcripts, which in turn suppresses mRNA and subsequent protein expression. In this review, we reported and characterized the many aberrant miRNA-CXCR4 interactions that occur throughout human cancers. In particular, we reported known target sequences located on the 3' UTR of CXCR4 transcripts that tumour suppressor miRNAs bind and therefore regulate expression by. From these aberrant interactions, we also documented affected downstream genes/pathways and whether a particular tumour suppressor miRNA was reported as a prognostic marker in its respected cancer type. In addition, a limited number of cancer-causing miRNAs coined 'oncomirs' were reported and described in relation to CXCR4 regulation. Moreover, the mechanisms underlying both tumour suppressor and oncomir deregulations concerning CXCR4 expression were also explored. Furthermore, the miR-146a-CXCR4 axis was delineated in oncoviral infected endothelial cells in the context of virus-causing cancers. Lastly, miRNA-driven therapies and CXCR4 antagonist drugs were discussed as potential future treatment options in reported cancers pertaining to deregulated miRNA-CXCR4 interactions.

Indexed as

MicroRNAsNeoplasms3' Untranslated RegionsDNA MethylationEndothelial CellsGene Expression Regulation, NeoplasticHumansReceptors, CXCR4RNA, Messenger3' Untranslated RegionsCXCR4 protein, humanMicroRNAsReceptors, CXCR4RNA, MessengerCXCR4MicroRNAmicroRNA mimicsoncomironcovirusestumour suppressor

Identifiers

PMID36047714
PMCPMC9665135
OpenAlexW4294053318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.